Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Trinity Biotech (TRIB) FCF Margin (2016 - 2024)

Historic FCF Margin for Trinity Biotech (TRIB) over the last 16 years, with Q4 2024 value amounting to 23.59%.

  • Trinity Biotech's FCF Margin rose 194200.0% to 23.59% in Q4 2024 from the same period last year, while for Jun 2025 it was 8.53%, marking a year-over-year increase of 140400.0%. This contributed to the annual value of 6.15% for FY2024, which is 127700.0% up from last year.
  • Per Trinity Biotech's latest filing, its FCF Margin stood at 23.59% for Q4 2024, which was up 194200.0% from 24.72% recorded in Q2 2024.
  • In the past 5 years, Trinity Biotech's FCF Margin ranged from a high of 45.3% in Q4 2020 and a low of 51.29% during Q2 2023
  • For the 5-year period, Trinity Biotech's FCF Margin averaged around 5.63%, with its median value being 4.17% (2023).
  • Per our database at Business Quant, Trinity Biotech's FCF Margin skyrocketed by 341200bps in 2020 and then plummeted by -512900bps in 2023.
  • Over the past 5 years, Trinity Biotech's FCF Margin (Quarter) stood at 45.3% in 2020, then plummeted by -49bps to 22.94% in 2021, then decreased by -23bps to 17.56% in 2022, then plummeted by -76bps to 4.17% in 2023, then surged by 466bps to 23.59% in 2024.
  • Its last three reported values are 23.59% in Q4 2024, 24.72% for Q2 2024, and 0.02% during Q1 2024.